Head and neck cancer, excl. thyroid

LBA35 - Avelumab-cetuximab-radiotherapy versus standards of care in patients with locally advanced squamous cell carcinoma of head and neck (LA-SCCHN): Randomized phase III GORTEC-REACH trial

Jean Bourhis , et al.


In cisplatin-Unfit pts, a favorable effect of adding avelumab to cetuximab was seen on PFS, local-regional control, distant metastases, but the primary endpoint on PFS was not met. In cisplatin-Fit pts, the futility boundary for efficacy was crossed, favoring SOC cisplatin.



LBA36 - Nivolumab (N) + ipilimumab (I) vs EXTREME as first-line (1L) treatment (tx) for recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): Final results of CheckMate 651

Athanassios Argiris, et al. 


N+I did not show statistically significant OS improvement vs EXTREME in pts with R/M SCCHN; however, there was evidence of clinical activity in pts with CPS ≥20 and CPS ≥1 as shown by prolonged OS (median and 2 y rates) and durable responses. Notably, OS in the control arm was better than historical data. N+I had a favorable safety profile vs EXTREME, with no new safety signals observed.



858O - Results of KEYNOTE-122: A phase III study of pembrolizumab (pembro) monotherapy vs chemotherapy (chemo) for platinum-pretreated, recurrent or metastatic (R/M) nasopharyngeal carcinoma (NPC)

Anthony T.C. T. , et al.


Pembro monotherapy did not improve OS vs chemo in pts with platinum-pretreated R/M NPC. PD-L1 CPS ≥1 did not enrich for OS or ORR for pembro. Pembro showed manageable safety and a lower incidence of treatment-related AEs vs chemo.



859O - Refining TNM staging system for Epstein-Barr virus-related nasopharyngeal carcinoma: A multicenter cohort study

Wang-Zhong Li, et al. 


We developed and validated an RPA-based staging system for EBV-related NPC. This staging system may facilitate prognostic stratification and clinical trial designs.